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PIEWPOINT AND COMMENTARY
fficacy and Safety in Clinical
rials in Cardiovascular Disease
ay N. Cohn, MD
inneapolis, Minnesota
Mortality and morbid events are insensitive guides to the efficacy and safety of interventions
in chronic cardiovascular disease (CVD). To enhance the ability to find new and effective
long-term treatments, especially for the early stages of CVD, a revised strategy for clinical
trials should emphasize efficacy on disease progression while monitoring symptoms and
quality of life as guides to clinical benefit. Mortality, which is uncommon except in acute or
advanced disease, provides at best a crude guide to net efficacy and safety. It must be
monitored to support demonstrated efficacy on disease progression without adverse safety
effects. This revised approach, made possible by our enhanced ability to monitor the
progression of disease, should make it possible to study earlier disease and to improve
cardiovascular health while reducing health care costs. (J Am Coll Cardiol 2006;48:430–3)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.083© 2006 by the American College of Cardiology Foundation
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rlinical trials are designed to assess the efficacy and safety of
nterventions to steer management. In recent years, all-cause
ortality has emerged as the primary end point in most
ardiovascular morbid conditions because it is a noncontro-
ersial outcome that appropriately is viewed as the most
erious unwanted consequence of the disease. Indeed, the
et effect on mortality has been used as a major factor in
egulatory approval of a drug and in choosing one regimen
ver another in diseases such as heart failure (HF) and acute
yocardial infarction (MI). In some trials, nonfatal morbid
vents, such as hospitalizations or MIs, have been added to
eaths to enhance the power of the end point to detect a
reatment effect.
This focus on mortality or defined morbid events as the
nd point for intervention trials is more common in cardio-
ascular diseases (CVDs) than in other clinical conditions.
rials in infectious diseases, arthritis, renal disease, gastro-
ntestinal disorders, or anemias could never choose a mor-
ality or morbid event end point. Even cancer therapy has
sually focused on nonmortality end points. This preoccu-
ation with mortality or morbid events reflects not only the
ecognition that CVD is the world’s major cause of death
ut also the perception that there are inadequate objective
riteria for its progression and its response to therapy. This
erception has justified unwieldy megatrials of painfully
ong duration to establish efficacy of therapy. It is time to
e-evaluate this perception in the light of new insights into
he mechanisms of the progression of CVD.
Prolongation of life is not the sole therapeutic goal of
nterventions in CVD. Symptoms, impaired quality of life,
urden on family and friends, and utilization of expensive
ealth care resources are perceived by many patients as of
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esota Medical School, Minneapolis, Minnesota.i
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006, accepted January 25, 2006.ore importance in their daily lives (1). The goals of CVD
reatment might be divided into 3 categories: 1) relieve
ymptoms that adversely affect quality of life; 2) slow disease
rogression that will ultimately lead to morbid events, a
orsening quality of life, and greater emotional and finan-
ial burden; and 3) delay deaths and morbid events, some of
hich may be complications of disease progression and
ome of mechanistically distinct origin.
Therapy may favorably affect 1 or more of these thera-
eutic targets, but not necessarily all. Furthermore, some
herapies may result in unwanted side effects that can
dversely affect 1 or more of these targets. For example,
eta-blockers may produce short-term aggravation of symp-
oms in HF but may slow progression of the disease and
rolong life (2). Complications of surgery or angioplasty
ay cause short-term mortality but may lead to long-term
enefit (3). Positive inotropic drugs may relieve symptoms
ut may increase the risk of arrhythmic deaths (4). Type I
ntiarrhythmics may relieve symptomatic palpitations but
ay do nothing for disease progression and may increase the
isk of sudden death (5). Implanted cardiac-defibrillators
an prevent sudden death but may induce new symptoms
nd not slow disease progression (6). In planning therapeu-
ic strategies and therapeutic trials, it would seem appropri-
te to target specifically 1 or more of these goals rather than
global “outcome” that does not distinguish the mechanis-
ic effect.
Prolonging survival must be a long-term goal of all
nterventions aimed at interfering with the progression of
hronic CVD. Mortality reduction during the follow-up
eriod of a time-limited clinical trial has served us well to
how the remarkable efficacy of angiotensin-converting
nzyme inhibitors (7) and beta-blockers (8) for HF, throm-
olytic therapy for acute MI (9), and statins for atheroscle-
osis (10). However, mortality as an end point, powerful as
t can be, suffers from several major deficiencies: 1) mortality
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August 1, 2006:430–3 Efficacy and Safety in Clinical Trialseduction is neither a sensitive nor a specific guide to the
fficacy of therapy on the disease process; 2) mortality
annot distinguish between efficacy and safety; 3) a mortal-
ty end point mandates the study of patients with advanced
isease likely to die; and 4) a long follow-up period is usually
equired to achieve the number of events required for
dequate power to detect a benefit. Each of these issues is
xamined in more detail.
ORTALITY REDUCTION
elaying death is certainly a long-term goal of treatment of
hronic progressive CVD. But is mortality reduction a
ensitive and specific guide to efficacy in a clinical trial?
lthough death is a noncontroversial event, the relationship
f the event to the disease process being treated often is
ontroversial. All-cause mortality has served as the primary
nd point in most large trials in CVD because attempts to
istinguish cardiovascular causes of death are sometimes
awed. Did the driver’s accident stem from a heart attack?
ould pneumonia have led to death in the absence of heart
isease? Death or morbid events resulting from noncardio-
ascular causes can thus dilute the measurement of efficacy.
urthermore, some cardiovascular events may be unrespon-
ive to targeted therapy. For example, a treatment for HF
ay not prevent MIs or strokes. Even if one could clearly
efine the deaths related to the disease process being
reated, it is intuitive that death is a late manifestation of
isease progression and that it impacts only a small propor-
ion of the study population during the course of a trial.
herefore, at best, all-cause mortality and even cardiovas-
ular morbidity are neither specific nor sensitive as a guide
o the favorable effect of an intervention on a specific CVD
rocess.
FFICACY VERSUS SAFETY
ortality alone does not allow for a distinction between
fficacy and safety. The importance of this distinction may
e critical. The absence of efficacy on any of the three
herapeutic goals renders a therapy useless, but efficacy
ounterbalanced by adverse safety effects could lead to
pecific measures to reduce risk. For example, adverse
ypokalemic effects of diuretics can be counteracted by
otassium supplementation, and consequences of arrhyth-
ogenic effects could be neutralized by implanting a defi-
rillator. If safety concerns are confined to an identifiable
ubgroup, then such a group could be excluded from the
herapy. These measures could therefore allow the efficacy
Abbreviations and Acronyms
CVD  cardiovascular disease
HF  heart failure
LV  left ventricle/ventricular
MI  myocardial infarctionffects of an intervention on one of the therapeutic goals to ae expressed. Relying on overall mortality in a trial does not
llow this distinction to become apparent.
DVANCED DISEASE
ortality and morbidity end point trials are usually event-
riven so that the power of the study to detect a favorable
ffect of the therapy is dependent on achieving a prestudy
stimated required number of events. This design mandates
hat the trial recruit patients with a high likelihood of
xperiencing a morbid event. The result, of course, is that
ntrance criteria often include markers for advanced disease,
.g., a very low left ventricular (LV) ejection fraction in HF
11), LV failure complicating acute MI (12), LV hypertro-
hy or diabetes complicating hypertension (13). A favorable
ffect of a therapy in this high-risk population is often
dvocated, however, for patients without these high-risk
ttributes. For example, although hypertension trials usually
arget uniquely high-risk individuals, the therapy is recom-
ended for everyone with high blood pressure (14).
Devotion to a mortality end point precludes the study of
arly disease not likely to result in death during the limited
ollow-up period of all clinical trials. Indeed, the challenge
o prevent advanced disease, which is the most effective way
o reduce burgeoning health care costs, cannot be met if
fficacy can only be assessed in trials powered for mortality
eduction.
ONG FOLLOW-UP
he creativity of the medical profession has led to a
emarkable rate of development of new and potentially
xciting therapies. Under the current guidelines, each of
hese experimental therapies must be subjected to large,
ong, and expensive trials to prove efficacy. Not only do
hese studies consume a large proportion of limited research
unds, but they also subject patients to long-term treatment
ith experimental drugs or placebos and many deaths before
fficacy or safety has been established. Does an earlier
fficacy end point not dependent on counting bodies exist?
f efficacy of an intervention on disease progression could be
stablished early in a trial, if mortality and morbidity tracked
ith disease progression, and if the adverse event profile was
cceptable, then the control therapy could be replaced with
he effective therapy before mortality reduction had reached
he magical p value associated with “significance.” Although
ore robust safety data are needed to identify infrequent but
otentially serious adverse effects of an intervention, such
ow-incidence events are rarely divulged before marketing
nd should mandate intensive postmarketing surveillance.
ONMORTALITY END POINTS
hronic CVD is a progressive process. The premature
eaths that complicate the disease are the result of its
rogression, often interrupted by sudden events such as
rrhythmias or clots. Although the addition of morbidity
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Efficacy and Safety in Clinical Trials August 1, 2006:430–3nd points (e.g., nonfatal MI or stroke, hospitalization for
F) to augment mortality as a guide to efficacy may
mprove sensitivity, the end result still is that the majority of
atients entered into the trial do not contribute to the end
oint and the nonfatal end points require adjudication that
an always be questioned.
Heart failure is a progressive disease in which structural
hanges in the LV advance (remodeling), neurohormonal
timulation increases, quality of life decreases, there is a
eed for hospitalization for worsening HF, and life expec-
ancy shortens (15). Mortality may be the hardest of these
nd points, but it is hardly the most sensitive. Furthermore,
udden death may result from adverse effects of drug
nterventions (digitalis [16], milrinone [4], vesnarinone
17]) without necessarily impacting on some other potential
fficacy parameter for the therapy. Any of the above markers
hat characterize advancing disease could serve as a guide to
he slowing of disease progression, but the most mechanistic
nd powerful has been a marker for chronic structural
emodeling of the LV, including chamber volume or di-
ension and ejection fraction measured at least 3 to 6
onths after institution of the experimental therapy (18–
2). Structural changes in the LV are usually accompanied
y comparable changes in the plasma level of B-type
atriuretic peptide (23).
How can a measure of disease progression be used in an
verall assessment of efficacy and safety? It is first necessary
o establish that the markers for disease progression are
ensitive and specific mechanistic guides to adverse out-
omes directly related to the disease under study. Consid-
rable supportive data relating LV structural remodeling to
utcome in HF already exist (18–22). Collection of confir-
atory data in future clinical trials is of critical importance.
ascular and cardiac structural changes and urinary albumin
n hypertension and endothelial dysfunction in atheroscle-
osis are candidate markers whose sensitivity and specificity
s guides to risk of events and to therapeutic effects on
isease progression need to be documented (24,25). These
otential markers for disease progression are distinct from
isk factors that are merely statistically related to disease
vents (26), and some previously used so-called surrogates,
uch as ventricular premature beats, which proved to be
isleading (5). These cardiac and vascular structural/
unctional measurements are not surrogates for the disease,
ut they in fact appear to represent the CVD itself.
Once we are convinced that these mechanistic guides can
rack progression of disease, we should be in a position to
dminister therapy to achieve a clear end point that can be
racked in all patients. Relief of symptoms and improved
uality of life are appropriate clinical targets, but slowing
isease progression in an effort to delay morbid events is
robably even more important. Efficacy and safety can be
onfirmed by tracking morbid events and deaths, which
hould trend with the data on disease progression. Rather
han powering trials for highly significant reductions in
vents, we must become comfortable with powering trials,epending on the therapeutic goal, for highly significant
enefits on softer clinical outcomes buttressed by evidence
or slowed disease progression with efficacy and safety
onfirmed by favorable directional changes in morbidity and
ortality. Composite end points that include adverse events
s well as quality of life and even markers for disease
rogression may be a useful strategy (27,28). Then it should
e possible to carry out smaller and more efficient therapeu-
ic trials, and of utmost importance, trials at earlier stages of
isease to preserve health rather than only to salvage those
ith advanced disease.
Our enhanced understanding of the progressive nature of
VD now provides us with the opportunity to track disease
n addition to events. Cardiovascular medicine must now
ocus its attention on early detection and effective interven-
ion to slow disease progression to delay costly and life-
erminating events until our patients’ rewarding lives have
nded. Such a strategy should both improve societal health
nd reduce health care costs. A change in trial design and
egulatory philosophy is necessary to achieve this goal.
eprint requests and correspondence: Dr. Jay N. Cohn, Cardio-
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